Pfizer CEO Albert Bourla on Monday claimed the pharmaceutical giant will be able to provide Seagen’s Cancer medication to the world at a scale that has not been seen before, Eagen’s with its $43 billion acquisition.

“We can add value to what Seagen is bringing,” Bourla said in a CNBC interview. “It’s more or less a situation like when mRNA was in our hands. “With our scale, with our capabilities, this is the same here,” the CEO added further.

Seagen is a pioneer in the development of antibody-drug conjugates, or ADCs, which are meant to destroy cancer cells while leaving healthy cells alone. According to Seagen’s website, ADCs use antibodies to deliver small molecule medications directly to a tumour site, which may reduce side effects and increase efficacy.

Bourla referred to ADCs as “one of the finest technologies to attack cancer,” comparing them to the successful Mrna, or messenger RNA, technology that the business collaborated with BioNTech to develop for Covid-19 vaccines. The Mrna Technology is mostly utilized to convey instructions to cells. mRNA technology is employed in Covid vaccinations to deceive the human immune system into producing antibodies against the virus.

“ADCs are turbocharged directed missiles that strike cancer cells and can make a significant difference,” he explained.

Pfizer’s cancer treatment portfolio will be bolstered by Seagen, which will deliver four approved cancer treatments with combined revenues of approximately $2 billion in 2022. Last year, Seagen’s leading selling Adcetris, which treats lymph system tumors, generated $839 million in sales. According to Seagen’s most recent financial report, this is a 19% increase over the previous year.

Padcev, a treatment for urinary tract cancer, also had a 33% increase in sales last year, reaching $451 million, according to the company.

The post Pfizer To Expand its Cancer-Treatment Capabilities appeared first on Insights Success.